Caldera Therapeutics Deal History & Licensing Activity
Caldera Therapeutics is a life sciences. Over the past three years, Caldera Therapeutics has been involved in 2 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (3 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Gastroenterology
Caldera Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Caldera Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CLD-423 (IL-23p19/TL1A bispecific) | Qyuns Therapeutics | Bispecific Antibodies | Phase 1 | license | Jun 2025 |
Caldera Therapeutics Pipeline Focus
Therapeutic areas and modalities where Caldera Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Caldera Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Caldera Therapeutics Licensing & Deal Activity
Caldera Therapeutics is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Caldera Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Caldera Therapeutics include Gastroenterology (3 deals and trials). In terms of modality, Caldera Therapeutics has shown particular interest in bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Caldera Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Caldera Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.